A Study of XW003 in Obese Participants With Obstructive Sleep Apnea Receiving Positive Airway Pressure Therapy

What Was Tested

The trial (phase 3) is built around Ecnoglutide for sleep apnea (obstructive).

It had two arms (groups): XW003 Injection (experimental) and Placebo (placebo comparator).

Once weekly.

Once weekly.

The registry classes the interventions as drug.

Who Took Part

Enrollment: 140 planned participants were the target.

It was open to people of any sex aged from 18 years up to 75 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Body mass index (BMI) ≥ 28.0 kg/m2;. The results of PSG meet the diagnosis criteria of OSA and with an AHI≥15 at screening;. Have been on PAP therapy for at least 3 consecutive months prior to screening and plan to continue PAP therapy during the study;. Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight.

The full record lists 4 inclusion and 10 exclusion criteria; among the exclusions: diagnosis of diabetes (except gestational diabetes), ketoacidosis or hypertonic state/coma;; respiratory and neuromuscular diseases that could interfere with the results of the trial;; diagnosis of obesity hypoventilation syndrome or daytime hypercapnia;.

How the Study Was Run

Design: randomized, parallel-group and double-blind.

Because people in this Ecnoglutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Groups ran in parallel: each of the sleep apnea (obstructive) participants stayed in one arm throughout.

As a double-blind Ecnoglutide study, the assignments were hidden from both participants and investigators until the end.

Those kept unaware of assignments: participant and investigator.

It started in 2026-03-02 with completion listed for 2028-06-19.

It ran at 1 site in China.

Its stated primary purpose is treatment.

What Was Measured

The main thing measured (primary outcome): Change from baseline in Apnea-Hypopnea Index (AHI) (time frame: at week 48).

It also tracked 4 secondary outcomes, for example Percent Change From Baseline in AHI, Percentage of Participants With AHI <5 or With AHI 5-14 With Epworth Sleepiness Scale (ESS) ≤10 and Percent Change From Baseline in body weight.

What This Means in Plain Language

Put simply, this is a phase 3, randomized trial of Ecnoglutide in 140 people with sleep apnea (obstructive).

It is still recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Ecnoglutide compound page, Sleep apnea (obstructive) research.